Comparison of glatiramer acetate (Copaxone®) and interferon β-1b (Betaferon®) in multiple sclerosis patients: an open-label 2-year follow-up
- 1 May 2002
- journal article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 197 (1-2) , 51-55
- https://doi.org/10.1016/s0022-510x(02)00047-3
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Interferons in the Treatment of Multiple SclerosisArchives of Neurology, 1998
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- Management of Multiple SclerosisNew England Journal of Medicine, 1997
- Copolymer 1: from basic research to clinical applicationCellular and Molecular Life Sciences, 1997
- Therapeutic advances: beta-interferon for multiple sclerosisJournal of Clinical Pharmacy & Therapeutics, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Management of patients receiving interferon beta-1b for multiple sclerosisNeurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisNew England Journal of Medicine, 1987
- Suppression of experimental allergic encephalomyelitis by a synthetic polypeptideEuropean Journal of Immunology, 1971